1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > Analysis of the Cardiac Biomarker Diagnostics Market 

Analysis of the Cardiac Biomarker Diagnostics Market 

  • September 2015
  • -
  • Frost & Sullivan
  • -
  • 116 pages

Analysis of the Cardiac Biomarker Diagnostics Market 

Key Findings

The overall US cardiac biomarker diagnostic market stands at $ million in 2014 and is predicted to grow to $ million by 2021 at a compound annual growth rate (CAGR) of %.

- The increasing adoption of point-of-care tests (POCTs) in the United States makes this segment the fastest growing, where it holds close to % of the cardiac biomarker market.

- There is an increasing number of publications discussing the importance of POCT in improving patient outcomes. This is spurring adoption rate at a clinical and ambulatory level.

- The POCT market for cardiac biomarkers is spurring the growth in this region.

- With the implementation of Affordable Care Act (ACA), there is a shift toward value-based care. This is increasing pressure on manufacturers to produce more cost efficient and efficient devices for consumers, especially in the hospital sector.

- Manufacturers are seeing the value of integrated and wholesome platform solutions in this emerging value-based system.

- Device companies like Medtronic are entering the cardiac space to provide telehealth solutions to patients. Siemens and Roche have a unique advantage due to their strong affiliation with their medical devices and pharmaceutical wings, respectively.

- Companies with different diagnostic wings have a unique advantage, as they can offer a more integrated solution to diagnose a patient.

- Still in the early stages, the cardiovascular segment has tremendous potential for personalized medicine. There is a movement toward this space similar to other fields, like oncology.

- In the future, heart failure therapy is going to utilize a combination of multiple markers for risk assessment and diagnosis. Many of these biomarker tests are going to combine into a panel test rather than compete individually.

- Products with a narrow therapeutic index, which can be dangerous either over- or underdosing, have a higher profitability capacity to develop companion diagnostic tests to determine sensitivity to the product.

- Companion diagnostics is a major opportunity for manufacturers as cardiovascular disease holds only % of the overall companion diagnostics market space.

- Integrating digital apps enables manufacturers to understand consumer behavior but also provide differentiated products compared to competitors.

- Manufacturers can begin to offer consultations and services for biomarker testing and not be exclusive to providing lab solutions.

Table Of Contents

Analysis of the Cardiac Biomarker Diagnostics Market 
1 EXECUTIVE SUMMARY

Executive Summary
1 Key Findings
2 Key Findings
3 Competitive Landscape
4 Scope and Segmentation
5 Key Questions This Study Will Answer
6 Measurements
7 CEO's Perspective
8 Key Companies to Watch
9 Executive Summary—3 Big Predictions

2 MARKET OVERVIEW

Market Overview
1 Cardiac Diagnostics Industry Overview
2 Cardiac Biomarkers Diagnostics Overview
3 Market Background
4 Market Background—Prevalence Rate
5 Cardiac Diagnostics Overview
6 Market Overview—Testing Procedure
7 Factors Influencing Adoptability of Tests
8 Defining Healthcare Trends in the Future

3 COMPETITIVE PLAYBOOK

Competitive Playbook
1 New Market Opportunities
2 New Market Opportunities
3 Solutions Provided by Top Companies
4 Important Partnerships—Cardiac Biomarker IVD Diagnostics
5 Emerging Biomarkers for MI and Clinical Strength

4 EMERGING BIOMARKERS

Emerging Biomarkers
1 LDTs—Role in Cardiac Diagnostics
2 Other Emerging Biomarkers

5 DRIVER AND RESTRAINTS—TOTAL CARDIAC BIOMARKER DIAGNOSTICS MARKET

Driver and Restraints—Total Cardiac Biomarker Diagnostics Market
1 Market Drivers
2 Drivers Explained
3 Drivers Explained
4 Drivers Explained
5 Market Restraints
6 Restraints Explained
7 Restraints Explained

6 FORECASTS AND TRENDS—TOTAL CARDIAC BIOMARKER DIAGNOSTICS MARKET

Forecasts and Trends—Total Cardiac Biomarker Diagnostics Market
1 Measurements
2 Forecast Assumptions and Definitions
3 Revenue Forecast
4 Revenue Forecast Discussion
5 Percent Revenue Breakdown by Segments
6 Segment Lifecycle Analysis

7 COMPETITIVE ENVIRONMENT

Competitive Environment
1 Market Share
2 Market Share Analysis
3 Overall Market Share Analysis
4 Top Competitors
5 Top Competitors
6 Top Competitors
7 Top Competitors
8 Top Competitors

8 POCT SEGMENT ANALYSIS

POCT Segment Analysis
1 Measurements
2 Revenue Forecast
3 Revenue Forecast Discussion
4 POCT—Segment Share
5 Segment Share Analysis
6 Competitive Value Matrix
7 Top POCT Devices in the US Market
8 Competitive Product Analysis
9 Competitive Product Analysis
10 Competitive Product Analysis
11 Competitive Product Analysis
12 Competitive Product Analysis

9 LAB-BASED SEGMENT ANALYSIS

Lab-based Segment Analysis
1 Measurements
2 Revenue Forecast
3 Revenue Forecast by Disease Type
4 Growth Rate by Cardiac Disease
5 Revenue Forecast Discussion
6 Revenue Forecast Discussion
7 Product Portfolio
8 Product Portfolio
9 Pricing Trends and Forecast
10 Segment Share
11 Segment Share Analysis
12 Segment Share Analysis
13 Competitive Value Matrix

10 THE FULL PICTURE—CARDIAC DIAGNOSTICS INDUSTRY OVERVIEW

The Full Picture—Cardiac Diagnostics Industry Overview
1 Cardiac Diagnostics Industry Overview
2 Partnership Trends—Medical Device Diagnostics

11 CARDIAC IMAGING DIAGNOSTICS

Cardiac Imaging Diagnostics
1 Industry Overview
2 Industry Overview by Application
3 New Market Opportunities
4 Imaging Technology—Role in Patient Continuum

12 ECG IN CARDIAC DIAGNOSTICS

ECG in Cardiac Diagnostics
1 Industry Overview
2 Cardiac Monitoring by Application
3 New Market Opportunities
4 ECG Technology—Role in Patient Continuum

13 OPPORTUNITIES

Opportunities
1 Opportunities—Companion Diagnostics
2 Opportunities—Companion Diagnostics
3 Opportunities—Companion Diagnostics
4 Opportunities—Companion Diagnostics
5 Digital Health and Diagnostics Inter Convergence Model—Cardiac Diagnostics
6 Opportunity—Convergence of Imaging and IVD
7 Opportunities—Key Companies to Watch

14 THE LAST WORD

The Last Word
1 The Last Word—3 Big Predictions
2 The Last Word—3 Big Predictions Discussion
3 The Last Word—3 Big Predictions Discussion
4 Legal Disclaimer

15 APPENDIX

Appendix
1 List of Others
2 Methodology
3 Learn More—Next Steps
4 List of Exhibits
5 List of Exhibits
6 List of Exhibits
7 List of Exhibits

List of Exhibits


Total Cardiac Biomarker Diagnostics Market: Competitive Landscape, US, 2014
Total Cardiac Biomarker Diagnostics Market: Market Engineering Measurements, US, 2014
Total Cardiac Biomarker Diagnostics Market: Industry Overview, US, 2014
Total Cardiac Biomarker Diagnostics Market: Market Overview, US, 2014
Cardiac Biomarker Diagnostics Prevalence Rate, US, 2009-2020
Total Cardiac Biomarker Diagnostics Market: Market Segmentation, US, 2014
Total Cardiac Biomarker Diagnostics Adoptability of Biomarker Tests, US, 2014
Total Cardiac Biomarker Diagnostics Market: Market Outlook, US, 2014 and 2024
Total Cardiac Biomarker Diagnostics Market: Game-changing Strategies, US, 2014
Total Cardiac Biomarker Diagnostics Market: Company Offerings, US, 2014
Total Cardiac Diagnostic Market: Notable Deals and Trends, US, 2011-2014
Net Improvement in Predicting of 30-day Mortality, Emerging Biomarkers, US, 2014
Total Cardiac Biomarker Diagnostics Market: LDTs vs FDA-approved Tests, US, 2014
Total Cardiac Biomarker Diagnostics Market: Emerging Biomarkers, US,2014
Total Cardiac Biomarker Diagnostics Market: Key Market Drivers, US, 2015-2020
Total Cardiac Biomarker Diagnostics Market: Key Market Restraints, US, 2015-2020
Total Cardiac Biomarker Diagnostics Market: Market Engineering Measurements, US, 2014
Total Cardiac Biomarker Diagnostics Market: Revenue Forecast, US, 2011-2021
Total Cardiac Biomarker Diagnostics Market: Percent Revenue Breakdown by Segment, US, 2014
Total Cardiac Biomarker Diagnostics Market: Percent Revenue Breakdown by Segment, US, 2021
Total Cardiac Biomarker Diagnostics Market: Segment Lifecycle Analysis, US, 2014
Total Cardiac Biomarker Diagnostics Market: Percent Revenue Breakdown, US, 2014
Total Cardiac Biomarkers Diagnostics Market: Company Market Share Analysis of Top 4 Participants, US, 2014
Total Cardiac Biomarker Diagnostics Market: SWOT Analysis, US, 2014
POCT Segment: Market Engineering Measurements, US, 2014
POCT Segment: Revenue Forecast, US, 2011-2021
POCT Segment: Percent Revenue Breakdown, US, 2014
POCT Segment: Company Segment Share Analysis by Top 4 Participants, US, 2014
POCT Segment: Competitive Analysis, US, 2014
POCT Segment: Product Analysis, US, 2014
POCT Segment: Top 10 products, US, 2014
Lab-based Tests Segment: Market Engineering Measurements, US, 2014
Lab-based Tests Segment: Revenue Forecast, US, 2011-2021
Lab-based Tests Segment: Revenue Forecast by Disease Type, US, 2011-2021
Lab-based Tests Segment: Growth Rate by Cardiac Disease, US, 2011-2021
Lab-based Tests Segment: Product Analysis, US, 2014
Lab-based Tests Segment: Average Price, US, 2009-2021
Lab-based Tests Segment: Percent Revenue Breakdown, US, 2014
Lab-based Tests Segment: Company Segment Share Analysis of Top 4 Participants, US, 2014
Lab-based Tests Segment: Company Segment Share Analysis of Top 4 Participants, US, 2014
Lab-based Tests Segment: Competitive Analysis, US, 2014
Total Cardiac Diagnostics Industry: Industry Overview, US, 2014
Total Cardiac Diagnostic Industry: Notable Deals and Trends, US, 2011-2014
Total Cardiac Diagnostics Industry: Industry Overview, US, 2014
Total Cardiac Diagnostics Industry: Overview by Application, US, 2014
Total Cardiac Diagnostics Industry: Game-changing Strategies, US, 2014
Total Cardiac Diagnostics Industry: Patient Continuum, US, 2014
Total Cardiac Diagnostics Industry: ECG, US, 2014
Total Cardiac Monitoring Market: Market Segmentation, US, 2014
Total Cardiac Monitoring Market: Game-changing Strategies, US, 2014
Total Cardiac Diagnostics Industry: Patient Continuum, US, 2014
Total Cardiac Diagnostic Industry: Companies Pursuing CDx Opportunities, US, 2013-2015
Total Cardiac Diagnostic Industry: Pipeline Drugs for Each Cardiovascular Disease, US, 2013-2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 12800
  • Industry report
  • August 2016
  • by Venture Planning Group

This unique report provides information not available from any other published source, including volume, sales, and leading supplier shares by test. This comprehensive five-country report identifies and ...

Europe Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

Europe Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 12800
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800.VPGMarketResearch.com's new report is a strategic analysis of the major business opportunities emerging in the ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.